Multiple Sclerosis (MS) remains a difficult and typically progressive disease, despite medications that are now available.  Dr. Steven Levy, CEO of MD Stem Cells and Study Director of the Neurologic Stem Cell Treatment (NEST) study, describes the study and how their research group sees the procedure fitting into the limited treatments available for MS patients.

“NEST offers a specific stem cell procedure that can be called a ‘Middle Option’ for MS patients,” explains Dr. Levy. “It is a ‘softer’ procedure for patients who would like to do more than medication, are interested in newer approaches, but do not want the stresses and potential risks of another approach under study called HSCT or Hematopoietic Stem Cell Transplantation. “

What is NEST?

NEST is the Neurologic Stem Cell Treatment study uses the patient’s own (autologous) bone marrow stem cells (BMSC) given intravenously and intranasally.  The entire procedure is done as an outpatient in a fully licensed surgical center under anesthesia and takes less than an hour.  No hospitalization is required.  Continued use of any MS medication or alternative medicines is permitted.  Dr. Levy was instrumental in developing the NEST study and directs the study.  

Why is NEST a ‘Middle Option’ for MS? 

Patients with MS who are not benefitting from medication, have side effects from medication, or may be concerned about progression may be good candidates for NEST.   NEST can offer a stem cell intervention which may potentially benefit their disease but is much simpler and much less difficult for patients to undergo than HSCT (described below).   “The goal in any progressive disease is to do what is necessary for the patient to potentially benefit but no more,” opines Dr. Levy. “ We see NEST as an approach that splits the choice between medication alone and HSCT.” 

How safe is NEST?

NEST is supervised by an Institutional Review Board- which reports to the National Institutes of Health (NIH) and is periodically assessed by FDA.  NEST is registered with the NIH on clinicaltrials.gov.  NEST is a regulated, clinical study reviewed annually. MD Stem Cells has been conducting clinical studies using bone marrow derived stem cells since 2012.  

No adverse events or complications have occurred for patients treated in NEST.  Patients do not receive any preparatory drugs or chemotherapy.  No immune suppression is needed or used.  NEST is a one-day outpatient procedure- there is no hospitalization.  The body’s own stem cells are used so there is no risk of transmissible infection.  There is no special preparation needed; the stem cells are harvested, separated and transferred back to the patient in the same operating room. 

How is NEST thought to potentially help MS?

Preclinical research suggests that Bone Marrow Stem Cells (BMSC) may help neurologic disease in at least 3 ways: 

Exosome / Microvesicle Production

The BMSC can release proteins and nucleic acids in small packets that can potentially help make neural cells stronger and more resilient  - this is called neuroprotection.  Nerve Growth Factor, Neurotrophic Factors, miRNA can help neural cells work better and survive stress.  BMSC can also transfer parts of themselves to damaged cells.  

Neuronal Transdifferentiation

BMSC may potentially turn into other cells including neurons.  

Immune Modulation:

BMSC can quiet abnormal immune system attacks while preserving normal functions such as fighting infections. 

BMSC circulate intravenously to get to the peripheral nerves and into the brain and spinal cord.  BMSC can reach the brain through the paraventricular organs where there is no blood-brain barrier.  When placed intranasal, they can follow cranial nerves to the brain.  It is hoped that treatment in NEST will help repair damaged neurons and support cells, help them function better and reduce relapses. 

What causes MS?

In MS the person’s own immune system mistakenly attacks the myelin sheaths that help neurons to transmit information. Myelin is the living outer membrane of helper cells that is tightly wrapped, sometimes hundreds of times, around the part of the neuron that carries the signals.  The ‘helpers’ are one type of glial cells- specialized nerve cells that make up about half the nervous system and help neurons to work.  The patient’s immune system begins to attack the myelin sheaths and creates scars that prevent normal transmission of information by the neurons. The exact reason remains unknown, but the process results in many neurologic problems.  MS has recently been reported to kill neurons directly, particularly the projection neurons in the outer layers of the brain. Search  Cambridge University Stem Cell Institute for details: www.stemcells.cam.ac.uk/news . 

What are the types of MS?

About 85% of MS patients present with the most common Relapsing-Remitting Multiple Sclerosis (RRMS) with symptoms that come and go.  But over time most will develop Secondary Progressive Multiple Sclerosis (SPMS) with further weakness, balance and walking issues.  Progressive means that the disease gets worse over time. Less commonly patients present with Primary Progressive (PPMS) about 10% of the time or Progressive Relapsing (PRMS) about 5% of the time with worsening being part of the early presentation.  

Can you treat MS with medication?

Patients are usually encouraged by their physicians to have medication treatment early in their disease, because research has found that MS may cause more damage during the initial stages.  Early treatment is thought to lower the relapse rate and reduce new damage.  Several drugs are used in RRMS to reduce relapses- others for SPMS, PPMS or PRMS.  Most are thought to suppress the body’s immune cells to help protect the myelin sheath.  All can have side effects- sometimes mild, sometimes more serious. Unfortunately, none have been shown to slow the advance of disability.   

What is HSCT treatment for MS? 

HSCT or Hematopoietic Stem Cell Transplantation is being studied as an approach that seeks to ‘reset’ the immune system and stop inflammation, typically for aggressive forms.  The procedure starts with collecting the stem cells from the person’s own bone marrow or blood.  Then a powerful mix of chemotherapy drugs is given over multiple days to kill or suppress immune cells in the body. The harvested stem cells are given back intravenously.  Hospitalization can be up to 160 days if there are serious side effects. It can take 3-6 months for the immune system to recover.  Several studies have been done with promising results of reduced relapses, however receiving high dose chemotherapy for multiple days to kill most cells in the immune system is a serious undertaking.  A good source of information on HSCT is  www.nationalmssociety.org - the National Multiple Sclerosis Society website. 

How do I apply for NEST?

As with any clinical study, results cannot be guaranteed, and it is not possible to predict whether an individual patient will improve from treatment or continue to have progression of their MS disease.  The purpose of the study is to potentially benefit patients as well as to gather data to determine whether statistical significance is present for any improvements.

Patients may receive information about the study by emailing the Study Director, Steven Levy MD,  at This email address is being protected from spambots. You need JavaScript enabled to view it.; using the ‘contact us’ page on the website www.mdstemcells.com; calling 954-417-5533 and leave a voice message with their telephone number; alternative number 203-423-9494 (no messaging). The Neurologic Stem Cell Treatment (NEST) study is enrolling patients with different neurologic diseases including Stroke (CVA), Traumatic Brain Injury (TBI), Multiple Sclerosis, Parkinsons, ALS, PSP, MSA, CADASIL, Peripheral Neuropathy and others.  MD Stem Cells has no grant support for NEST and is not a pharmaceutical company; this is a patient sponsored study and the patients pay for both treatment and travel.

Hon. Prof. Dr. Nicolas Tzenios (creator of "KetoTv" and Chairman of TRCGEN+ medical research hub) has signed on to conduct a clinical trial with KGK Science Inc. The study will explore Hon. Prof. Tzenios 'Friendly LDL Theory' which suggests that in the absence of elevated glucose, low-density lipoprotein (LDL) does not oxidize or form plaque and has anti-inflammatory effects.

With this research, Hon. Prof. Tzenios hopes to prove that elevated glucose, rather than fat, is to blame for the onset of cardiovascular and diet-related diseases. If corroborated, his theory has the potential to greatly impact the realm of dietary science.

"Beginning with this trial, dietary medicine could change forever," says Hon. Prof. Tzenios. "Next, I hope to combine my efforts with those of other researchers—together, we could transform future scientific endeavours."

Hon.Prof. Tzenios is an expert in this field, having created literature and courses surrounding "Nic's Keto Diet" which also involves a combination of intermittent fasting, mindful eating and emphasis on organic products.

“In the absence of elevated glucose low-density lipoprotein (LDL) does not oxidize or form plaque and has anti-inflammatory effects.”

"We will make fat great again" is just one of Nicolas's jokes in his very serious and scientific approach to this Medical issue.

Hon. Prof. Nicolas is dedicating the results of this research to his late mother Alice, hoping in her memory to work hard to make the world a healthier place to all its inhabitants.

About Hon. Prof. Dr. Nicolas Tzenios

Prof. Dr. Nicolas Tzenios is the author of "Nic's Keto Diet," a book which is now available in four languages. He has also created a Keto postgraduate course, which is taught in universities and colleges across the globe.

About KGK Science Inc.

As a global Contract Research Organization (CRO), KGK Science performs a productive and pioneering role in the realm of scientific study. For over two decades, it has offered well-designed, customized solutions to each of its clients, consolidating its scientific, clinical, commercial, and regulatory abilities into one full-service package. Equipped with state-of-the-art technologies, novel research techniques, and a seasoned team of thought leaders, KGK Science remains at the forefront of its industry. And, by seamlessly matching its experience with its drive for innovation, this CRO is able to respond effectively to expanding trade and consumer demands.

About KetoTv

Keto Tv is a dedicated Keto channel (http://www.youtube.com/c/KETOTV1) with over 1.6 million views in less than 5 month.

About TRCGEN+

TRCGEN+ sponsor Medical research clinical trials including keto diet effects and a genetic research related to specific genetic cancer treatment approach with Kursk State Medical University.

Balearic Island, Majorca – Dynamic Detox, a world-renowned colonic irrigation and intestinal cleanse retreat, recently announced the addition of new booking dates for its treatment programme. The resort is located within the Iberostar Grand Hotel in Majorca. It has added 20–28 July and 3–11 August 2019, to its programme calendar. Dynamic Detox announced the move in order to accommodate higher demand from clientele.

In the nine-day programme, participants receive private consultations and treatments from Raaul Cohen, founder of Dynamic Detox. Cohen is an experienced colonic hydrotherapist, living and working in Majorca since 1999. Each programme at the resort accepts only six clients per session. The combination of limited availability and in-depth holistic treatments attracts clients from around the globe, including celebrities and politicians. Dynamic Detox hopes to meet demand for the best colon cleanse and gut treatments by adding new sessions in July and August.

Individuals will often join a detox retreat – or detox holiday, as some call it – as a way to address myriad health issues. Dynamic Detox combines different treatments, including juice fasts, enemas, and personalised nutrition counselling. These purportedly induce mental clarity and physical refreshment via a thorough bowel cleanse and for many people unwanted weight falls away.

As more research emerges, medical professionals increasingly agree that a well-functioning gut is critical for good health. The human gut houses hundreds of types of bacteria, some of which may be detrimental to wellness. Harmful gut bacteria is linked to diseases like cancer, diabetes, inflammatory bowel diseases, and more. Enemas, fasts, and colonic cleanses are thought to clear our harmful bacteria from the body while promoting the growth of helpful bacteria.

After the treatment concludes, Dynamic Detox clients often report relief from a variety of chronic conditions such as asthma, digestive problems, headaches, yeast infections and as well as feeling generally healthier and more active. This, Raaul says, is the ultimate goal of his programme – improving wellbeing through a gut cleanse and personalised nutritional planning. Those interested in booking a stay at Dynamic Detox can visit the official website to view availability for all future sessions.

Contact Name: Raaul Cohen

Contact Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

https://cleanbreaks.net/booking/

About: Dynamic Detox is a luxury resort for gut detoxification and bowel cleanses, based in Majorca. Raaul Cohen, an internationally-renowned hydrotherapist and naturopath, runs the detox programme.

Dynamic Detox
Hotel Iberostar Grand Hotel
Calle Falconer 19
07181 Portals Nous Balearic Island
Majorca
+34 971 701 708
https://www.cleanbreaks.net

Tampa, FL – ABISA, LLC, a leading independent healthcare consultancy, announced that the company has now engaged clients in Canada and is working with them to help advance their healthcare business initiatives.

In addition to its longstanding U.S. client base, ABISA also has worked with clients in the United Kingdom, United Arab Emirates, Virgin Islands, Australia, South Africa, Switzerland, Morocco, Puerto Rico, and Turkey.  “We are excited with the company’s continued international expansion,” says Nick Hernandez, CEO at ABISA. "ABISA’s niche within the healthcare industry positions us well for the strategic needs of our clients.”

Investors and healthcare providers are seeking support for a variety of strategic business initiatives to expand markets.  ABISA is an ideal partner to provide that consulting support. The company’s success can be attributed to its culture that focuses on professionalism and emphasizes long-term client relationships.  “We are very pleased to have been selected to work with these projects,” Hernandez said. “The global healthcare sector is ever-changing. Selecting the right partner to support critical initiatives is so important. Our integrity and focused expertise allows our clients to be confident that ABISA will provide the sound advice that they expect.”

About ABISA

ABISA is a global healthcare consultancy specializing in healthcare strategy and physician engagement, healthcare investment initiatives, and global oncology initiatives.  ABISA can help devise and implement the strategies and processes that will allow organizations to remain competitive and solvent. For more information, visit www.abisallc.com

The first thing our doctor noticed the day after his patient received the ACIST stem cells was her saying hello to him in a heartwarming fashion- completely different from the day before treatment when she was quiet and withdrawn. Post-op day one was a new beginning for this beloved mother and her daughter, fighting moms Alzheimers disease together.  

When I brought the car to start driving her home, my mother got in and instead of being confused and trying to put the safety belt into the door as was typical, she put it in the buckle! excitedly explained her daughter during a call while driving home that same day. 

Her mother had enrolled in MD Stem Cells new Alzheimers Autism Cognitive Impairment Stem Cell Treatment Study or ACIST.  This is the first open-label, non-randomized study designed for patients with dementias, including Alzheimers, treating them with their own bone marrow stem cells called BMSC.  All enrolled patients receive active BMSC treatment- there is no placebo arm- making it different from most drug studies.  The ACIST study is  registered with the National Institutes of Health on their www.clinicaltrials.gov website NCT number 3724136.  

Dementia is a condition where memories and the ability to think logically are progressively lost.  There are several causes of dementia including Alzheimers (ALZ), Lewy Body, Vascular, CADASIL, Parkinsons, Stroke, Traumatic Brain Injury, Chronic Traumatic Encephalopathy and other conditions that can affect neurons in the brain.  Care for ALZ sometimes includes medicine such as Aricept or Memantine that can temporarily keep neurotransmitters more active.  But there is still no drug or therapy that can stop the disease progression.  For years research focused on preventing or removing Beta-amyloid, a protein that builds up abnormally in Alzheimers- but no benefit has ultimately been proven using this approach. Unfortunately, the possible drug development solutions to reverse ALZ or other dementias have diminished reports Dr. Steven Levy, co-developer of the ACIST study, Study Director and CEO of MD Stem Cells. I think most researchers would agree that new approaches are desperately needed.

Now home, the patient spontaneously dressed herself one morning- the first time in many months- surprising and delighting her daughter.  For the first time in years she ordered tea when they were out, something she used to love but had forgotten about because of her disease.  Rather than staring at the floor during the time with her daughter, she was much more alert and engaged.  Formal testing with the Mini-Mental Status Exam will come soon, but improvement in real world activities is much more important to a family.  

BMSC have the ability to circulate multiple times and enter the brain and spinal fluid through our extremely safe application approach.  They have intrinsic repair and neuroprotection functions that may benefit this disease, explains Dr. Levy.  Our physician group is very pleased that certain activities of daily living have improved so early for this patient, presumably because the memories of how to do them have been recovered.  We hope this points the way to further benefit. 

ACIST is a clinical study and individual responses cannot be predicted. It is not known if participant improvements, if any, will be maintained. There are specific inclusion, exclusion and follow up requirements to participate. This is a patient sponsored study and there are direct costs to the patient which are not covered by insurance. Patients  interested in learning whether they may be eligible to participate in ACIST, as well as healthcare providers seeking information, may email Dr. Levy at This email address is being protected from spambots. You need JavaScript enabled to view it. or call him at 203-423-9494 Eastern Time USA.

Tampa, FL – ABISA, LLC, a leading independent healthcare consultancy, announced that the company has now engaged oncology clients in South Africa and is working with them to help advance healthcare business initiatives in that country.

In addition to its longstanding U.S. client base, ABISA also has worked with clients in the United Kingdom, United Arab Emirates, Virgin Islands, Morocco, Puerto Rico, Australia, Turkey, and Switzerland.  “We are excited with the company’s continued international expansion,” says Nick Hernandez, CEO at ABISA. "ABISA’s niche within the healthcare industry positions us well for the strategic needs of our clients.”

Investors and healthcare providers are seeking support for a variety of strategic business initiatives to expand markets.  ABISA is an ideal partner to provide that consulting support. The company’s success can be attributed to its culture that focuses on professionalism and emphasizes long-term client relationships.  “We are very pleased to have been selected to work with these projects,” Hernandez said. “The global healthcare sector is ever-changing. Selecting the right partner to support critical initiatives is so important. Our integrity and focused expertise allows our clients to be confident that ABISA will provide the sound advice that they expect.”

About ABISA

ABISA is a global healthcare consultancy specializing on healthcare strategy and physician engagement, strategic telehealth initiatives, and global oncology initiatives.  ABISA can help devise and implement the strategies and processes that will allow organizations to remain competitive and solvent. For more information, visit www.abisallc.com or contact us at This email address is being protected from spambots. You need JavaScript enabled to view it..

What exactly is CBD? One of the main components in the cannabis plant is Cannabidiol or CBD. While studies and research are relatively small in scope, the results are quite promising when it comes to CBD (cannabidiol). CBD has been the subject of many studies which examined its effect on dozens of health issues: pain, cancer, anxiety, diabetes, fibromyalgia, PTSD, schizophrenia, MS, and dementia. The best part -- CBD produces a beneficial effect without getting you high.

Regardless of its recent popularity, there is still confusion about CBD products, how they are made, and what they can do for you. That is why well-renowned CBD brand Blue Moon Hemp is determined to spread awareness about the Endocannabinoid System and its beneficial effects on the body and overall wellness. Their mission is to educate the public on the many and varied nutritional and health benefits of CBD oil, to help optimize purity in formulation, and to find new product delivery systems.

The company offers a variety of CBD products including tinctures, e-liquids, salve, shatter, and edibles. CBD is versatile and can be consumed a variety of ways: you can vape it, enjoy an edible gummy, drop some CBD oil on your tongue, or use it topically (lots of wellness and beauty products use cannabidiol). Not all CBD hemp oils are alike in terms of quality. While most hemp is still imported from other countries, domestic hemp production is growing rapidly. Blue Moon Hemp`s Kentucky-grown hemp produces the highest levels of CBD without any pesticides, heavy metals or toxins. The farms are eco-friendly and use sustainable farming and production methods. The company offers detailed lab reports on their products, so customers always know what they're getting. Moreover, Blue Moon Hemp products are considered raw, vegan, gluten-free, non-GMO, soy free and nut free.

CBD oil is a sweetheart of the plant community. Its consumption and production grow every day with new companies and products popping up all over the world. Brightfield Group projected that the cannabidiol industry may reach $22 billion in market size by 2022. With so much potential, it seems new CBD products enter the market daily. Cannabidiol may well be the medicine of the future.

Blue Moon Hemp is dedicated to bringing together the best farmers, growing methods, researchers, and laboratory partners to create products that have a positive impact on a person`s well-being and life. The company continues to expand due to the surge in demand and increased awareness and acceptance of CBD and its potential benefits.

More information can be found at www.BlueMoonHemp.com.

DALLAS, TX, September 6, 2018 - ProPath is pleased to announce that it has become a Preferred Provider of Promegas Microsatellite Instability (MSI) Analysis System for use in clinical trials.  ProPath has over seven years of experience with Promegas MSI technology, the gold standard in determining MSI status, and has analyzed thousands of specimens.  In addition, the two companies will conduct collaborative research studies on applications and advantages of new MSI markers developed by Promega. 

MSI testing detects DNA mismatch repair (MMR) deficiency in tumor tissue.  It was originally developed as an aid to help identify if further testing was needed to determine Lynch Syndrome, an inherited genetic disorder that predisposes individuals to developing cancer.  More recently, the MMR deficiency-MSI complex has been recognized as a powerful biomarker for predicting response to a group of cancer therapeutics called checkpoint inhibitors.  These new drugs have demonstrated significant potential to greatly impact cancer care. 

 This announcement further underscores the commitment Promega and ProPath are making to advancing microsatellite instability as an important marker in evaluating tumor status, noted Dr. Heather Tomlinson, Director of Clinical Diagnostics. The MSI Assay is reimbursable, has a fast turnaround time and most importantly there is a large body of evidence supporting use of the Promegas MSI assay as part of a lab-developed test. Promega announced their intent to seek FDA approval with their MSI assay last year.

We are excited to partner with a great company like Promega in providing MSI testing. said Dr. Cory Roberts, President and CEO of ProPath. Promegas market-leading expertise complements our experience in delivering the most accurate, timely results.

About ProPath

ProPath is a physician-owned pathology practice with over 40 board-certified, sub-specialty trained pathologists, providing diagnostic expertise and conducting research for all cancer types.  In addition to the Promega MSI test, ProPath offers a large menu of diagnostic, prognostic, and predictive assays for optimizing the personalized selection of therapeutics.

www.propath.com

Salt Lake City, UT – Allergists and immunologists from across the country attended the American Academy of Allergy, Asthma & Immunology conference this past weekend at the Little America Hotel in Salt Lake City.  One of the invited faculty members was Nick Hernandez, the Founder and CEO at ABISA, LLC.

Mr. Hernandez presented three highly engaging sessions over the three day conference.  Physicians in attendance heard his presentations on key indicators for a healthy practice, demonstrating value in a private practice setting, and implementing telehealth in an allergy practice.

The CEO of a leading independent healthcare consultancy, Nick has helped clients throughout the United States and in multiple countries formulate strategic direction and advance healthcare business initiatives.  The company’s client list includes physician groups, hospitals, healthcare IT organizations, venture capitalists, private equity investment groups, and strategy consulting companies.

About ABISA

ABISA offers a comprehensive range of consulting services tailored for the needs of healthcare providers.  As a trusted source for operational solutions, ABISA enables physicians to concentrate more of their time on patient care.  For more information, visit www.abisallc.com.  

About the American Academy of Allergy, Asthma & Immunology

The American Academy of Allergy, Asthma & Immunology a professional organization with nearly 7,000 members in the United States, Canada and 72 other countries. This membership includes allergist / immunologists, other medical specialists, allied health and related healthcare professionals—all with a special interest in the research and treatment of allergic and immunologic diseases. For more information, visit www.aaaai.org.